DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Teveten (Eprosartan Mesylate) - Published Studies

 
 



Teveten Related Published Studies

Well-designed clinical trials related to Teveten (Eprosartan)

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. [2010.02]

Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. [2009.12]

Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound. [2008.09]

Effect of eprosartan on the sympathetic response to cold pressor test in healthy volunteers. [2006.06.30]

Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. [2006.02]

Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. [2005.10]

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). [2005.06]

Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia. [2005.02]

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. [2004.09]

A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. [2004.07]

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. [2004.07]

Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. [2004]

[Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability] [2004]

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. [2003.08.29]

Elevation of sympathetic activity by eprosartan in young male subjects. [2003.08]

Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. [2002.04]

Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. [2002.03]

Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. [2001.12]

Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. [2001.12]

Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. [2001.12]

ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. [2001.05]

Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. [2001]

Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. [2001]

Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. [2000.06]

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. [1999.07]

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. [1999.06]

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. [1999.03]

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. [1999.01]

Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. [1999]

Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. [1999]

Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. [1999]

Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. [1999]

Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group. [1999]

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. [1998.09]

Eprosartan does not affect the pharmacodynamics of warfarin. [1998.07]

The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. [1998.05]

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. [1998.04]

Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. [1998.03]

A dose proportionality study of eprosartan in healthy male volunteers. [1998.01]

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. [1997.10]

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. [1997.06]

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. [1997.02]

Well-designed clinical trials possibly related to Teveten (Eprosartan)

Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs: A Systematic Review and Meta-Analysis. [2009]

Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension. [2008.04]

Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. [2006.04]

Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. [2006.01]

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. [2005.07]

Losartan increases bradykinin levels in hypertensive humans. [2005.01.25]

Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress. [2003.02]

Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. [2003.02]

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. [2002.07]

AT1 blockers and uric acid metabolism: are there relevant differences? [2002.06]

Other research related to Teveten (Eprosartan)

Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials. [2012]

Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials. [2011.09.01]

The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension. [2011.09]

The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension. [2011]

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). [2010.06]

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. [2010]

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. [2009.09]

Comparative Effects of Telmisartan and Eprosartan on Insulin Sensitivity in the Treatment of Overweight Hypertensive Patients. [2009.08.25]

Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats. [2009.05]

Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. [2009.03]

Eprosartan: a review of its use in hypertension. [2009]

Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study. [2009]

Clinical profile of eprosartan: a different angiotensin II receptor blocker. [2008.10]

Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. [2008.08]

Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension. [2008.07]

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. [2008.06]

Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans. [2008.03.13]

Effectiveness of eprosartan in diabetic hypertensive patients. [2008.01]

Angiotensin blockade with eprosartan: vascular and functional implications. [2007.11]

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline. [2007.11]

Effects of eprosartan on target organ protection. [2006]

Principal Results of a Prospective Randomised Controlled Study: Morbidity and Mortality after Stroke Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES). [2005.12]

[Effect of a combination of teveten and prestarium in patients with chronic heart failure] [2005.06]

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. [2005.04]

Principal Results of a Prospective Randomised Controlled Study: Morbidity and Mortality after Stroke Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES). [2005.01]

Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. [2005]

Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. [2004.12]

Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. [2004.11]

A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285]. [2004.10.01]

The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. [2004.10]

Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting. [2004.10]

Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. [2004.09]

[Anti-hypertensive effect of eprosartan in diabetic patients] [2004.05]

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. [2004.03]

Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies. [2004.01]

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. [2003.01]

Eprosartan for the treatment of hypertension. [2003.01]

Clinical profile of eprosartan. [2002.12]

The clinical profile of the angiotensin II receptor blocker eprosartan. [2002.06]

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. [2002.04]

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). [2002.03.15]

Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension. [2002.01]

Safety and tolerability of eprosartan in combination with hydrochlorothiazide. [2002]

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure. [2001.09]

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. [2001.06]

Eprosartan: a review of its use in the management of hypertension. [2000.07]

Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. [2000.07]

Dehydration behavior of eprosartan mesylate dihydrate. [1999.10]

Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. [1999.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017